18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters
Autor: | Bing Shi, Timothy D. Ely, Mark M. Goodman, John M. Hoffman, John R. Votaw, Michael J. Owens, Vernon M. Camp, Robert Keil, Eugene Malveaux, Dongxia Xing, Clinton D. Kilts, Philip D. Lambert, Laurent Martarello |
---|---|
Rok vydání: | 2000 |
Předmět: |
Male
Fluorine Radioisotopes Cancer Research Nortropanes Nerve Tissue Proteins Ligands Dopamine agonist Rats Sprague-Dawley Mice Dogs In vivo medicine Radioligand Animals Humans Tissue Distribution Radiology Nuclear Medicine and imaging Biotransformation Chromatography High Pressure Liquid Serotonin transporter Dopamine transporter Dopamine Plasma Membrane Transport Proteins Membrane Glycoproteins biology Chemistry Putamen Radiochemistry Brain Membrane Transport Proteins Nisoxetine Macaca mulatta Rats Biochemistry Norepinephrine transporter Injections Intravenous biology.protein Autoradiography Molecular Medicine Carrier Proteins Half-Life Tomography Emission-Computed medicine.drug |
Zdroj: | Nuclear Medicine and Biology. 27:1-12 |
ISSN: | 0969-8051 |
Popis: | Fluorine-18 labeled 2beta-carbomethoxy-3beta-(4-chlorophenyl)-8-(2-fluoroethyl)nort ropane (FECNT) was synthesized in the development of a dopamine transporter (DAT) imaging ligand for positron emission tomography (PET). The methods of radiolabeling and ligand synthesis of FECNT, and the results of the in vitro characterization and in vivo tissue distribution in rats and in vivo PET imaging in rhesus monkeys of [18F]FECNT are described. Fluorine-18 was introduced into 2beta-carbomethoxy-3beta-(4-chlorophenyl)-8-(2-fluoroethyl)nort ropane (4) by preparation of 1-[18F]fluoro-2-tosyloxyethane (2) followed by alkylation of 2beta-carbomethoxy-3beta-(4-chlorophenyl)nortropane (3) in 21% radiochemical yield (decay corrected to end of bombardment [EOB]). Competition binding in cells stably expressing the transfected human DAT serotonin transporter (SERT) and norepinephrine transporter (NET) labeled by [3H]WIN 35428, [3H]citalopram, and [3H]nisoxetine, respectively, indicated the following order of DAT affinity: GBR 12909 > CIT >> 2beta-carbomethoxy-3beta-(4-chlorophenyl)-8-(3-fluoropropyl) nortropane (FPCT) > FECNT. The affinity of FECNT for SERT and NET was 25- and 156-fold lower, respectively, than for DAT. Blocking studies were performed in rats with a series of transporter-specific agents and demonstrated that the brain uptake of [18F]FECNT was selective and specific for DAT-rich regions. PET brain imaging studies in monkeys demonstrated high [18F]FECNT uptake in the caudate and putamen that resulted in caudate-to-cerebellum and putamen-to-cerebellum ratios of 10.5 at 60 min. [18F]FECNT uptake in the caudate/putamen peaked in less than 75 min and exhibited higher caudate- and putamen-to-cerebellum ratios at transient equilibrium than reported for 11C-WIN 35,428, [11C]CIT/RTI-55, or [18F]beta-CIT-FP. Analysis of monkey arterial plasma samples using high performance liquid chromatography determined that there was no detectable formation of lipophilic radiolabeled metabolites capable of entering the brain. In equilibrium displacement experiments with CIT in rhesus monkeys, radioactivity in the putamen was displaced with an average half-time of 10.2 min. These results indicate that [18F]FECNT is a radioligand that is superior to 11C-WIN 35,428, [11C]CIT/RTI-55, [18F]beta-CIT-FP, and [18F]FPCT for mapping brain DAT in humans using PET. |
Databáze: | OpenAIRE |
Externí odkaz: |